Home of Hepatology7 rue Daubin1203 GenevaSwitzerland+41 22 807 03 60easloffice@easloffice.eu© 2025 EASL. All rights reserved.Website by Soto.Privacy Policy | Cookie Policy | Terms & Conditions | Cyber Security Explore offerUnlock the full potential of being part of the EASLcommunity. As a member, you’ll gain access toexclusive resources, reduced event fees, top-tierjournals, and professional development opportunitiesdesigned to support your career in hepatologyBecome a memberNurses & Allied Health ProfessionalsLink titleYoung InvestigatorsLink titleBasic ScienceLink titleTitle here Lorem ipsum At the heart of EASL is a diverse and dynamic international community of professionals dedicated to advancing hepatology.Discover how you can get involved and make an impact.Whether you're a member, a Young Investigator, a nurse or allied health professional, or focused on basic science, there's a place for you here. Explore the different pathways to connect, grow and contribute, from membership benefits to tailored programmes and scientific networksLorem ipsum dolor sit ipsum CommunitySign In / Sign UpResourcesWhat We DoAbout Us Partnerships

EASL

EASL News

EASL General Assembly elects new Board and Committee members

The General Assembly of the European Association for the Study of the Liver (EASL) has elected new members to its Governing Board, various committees and a new Editor-In-Chief for its Journal of Hepatology. 12 April 2019 – Vienna, Austria The European Association for the Study of the Liver (EASL)…

EASL News

Transforming the landscape of liver disease in the UK

Perspectum Diagnostics released details regarding the latest version of its LiverMultiScan magnetic resonance imaging technology which identified nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, according to a press release. The latest version of LiverMultiScan, known as LiverMu…

EASL News

Fatty liver imposes 91% higher risk for cancer

San Francisco — Patients with non-alcoholic fatty liver disease carried a 91% higher risk for malignancy and the risk for cancer with obesity is “driven by NAFLD,” according to a presentation at The Liver Meeting 2018. “The risk of malignancy was higher in NAFLD vs. controls … 91% higher than the…

Scroll to Top

Search EASL